Our History, Investments, Projects, Achievements

Eris Pharmaceuticals (Eris Pharma) was founded.

• Eris Pharmaceuticals (Eris Pharma), established in 2009, represents one of Eris Enterprises’ key ventures. The company initially entered a joint venture with Australia’s Ascent Pharmahealth in 2010 and later became part of Watson (now Actavis) following Ascent’s acquisition in 2012. By the end of that year, Eris Pharma regained independence through a management buyout, positioning itself for autonomous growth.

Strategic acquisitions and partnerships followed, including the majority share acquisition by Switzerland’s FMH Group in 2013, the establishment of dedicated business units for Emerging Markets and the Australia & New Zealand regions, and the acquisition of Aurobindo Australia in 2015. By 2016, Eris Enterprises had successfully exited its shareholding venture, completing a significant phase of expansion and consolidation.

Building on this experience, Eris Enterprises undertook the strategic transformation of Adelco Pharmaceuticals & Cosmetics, Greece’s oldest manufacturer of medicines and cosmetics. Collaboration started Q4 2016, with the appointment of Panos Athanasiou as General Manager, the initiative focused on modernizing operations, renovating factories, improving ERP systems, developing new products, and expanding licensing portfolios.

As part of Adelco’s international growth strategy, Eris Enterprises established Adelco Pharmaceuticals Australia Pty Ltd (Melbourne) and Adelco MENA Jordan Ltd (Amman) to serve the Australian and Middle Eastern markets, respectively. Over the period 2016–2024, the company achieved TGA factory approvals, marketing authorizations for OTC products, strategic manufacturing and distribution partnerships, and regulatory approvals across the MENA region, while investing in modernized facilities, new product launches, and expanded R&D initiatives.

Eris Enterprises has collaborated with Bennett Pharmaceuticals SA since 2024, offering strategic advisory services in business development, product strategy, and M&A activities.

Continuing its commitment to innovation and client-focused solutions Eris Enterprises, founded in 2025, AVG Laboratories by Eris S.A. a new company specializing in added-value generics and fixed combinations pharmaceuticals product development. Based in Thessaloniki with new R&D Laboratory and  with offices in Athens, Greece, AVG Laboratories provides complete development dossiers, performs tech transfers and offers analytical services enabling clients to bring new pharmaceutical products to market efficiently and reliably.

“Moving Forward”
Today, Eris Enterprises continues to invest in cutting-edge research, strategic partnerships, and international business development, delivering high-quality, specialized pharmaceutical solutions to diverse healthcare markets worldwide. The company remains committed to innovation, collaboration, and creating long-term value across the global pharmaceutical landscape.